• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Applied DNA Sciences Inc.

    11/14/24 5:46:25 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary
    Get the next $APDN alert in real time by email
    SC 13G 1 d834912dsc13g.htm SC 13G SC 13G

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, DC 20549

     

     

    SCHEDULE 13G

    (Rule 13d-102)

    (Amendment No.)

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO

    RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO RULE 13d-2(b)

     

     

    APPLIED DNA SCIENCES, INC.

    (Name of Issuer)

    Common Stock, $0.001 par value

    (Title of Class of Securities)

    03815U409

    (CUSIP Number)

    September 30, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒ Rule 13d-1(b)

    ☐ Rule 13d-1(c)

    ☐ Rule 13d-1(d)

     

     

     


    CUSIP No. 03815U409    13G   

     

     1   

     NAME OF REPORTING PERSONS

     I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

     Anson Funds Management LP

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Texas

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     1,143,104*

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     1,143,104*

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     1,143,104*

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     9.9% **

    12  

     TYPE OF REPORTING PERSON*

     

     IA, PN

     

    *

    SEE INSTRUCTIONS BEFORE FILLING OUT

    **

    SEE ITEM 4(b).

     

    2


    CUSIP No. 03815U409    13G   

     

     1   

     NAME OF REPORTING PERSONS

     I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

     Anson Management GP LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Texas

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     1,143,104*

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     1,143,104*

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     1,143,104*

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     9.9% **

    12  

     TYPE OF REPORTING PERSON*

     

     HC, OO

     

    *

    SEE INSTRUCTIONS BEFORE FILLING OUT

    **

    SEE ITEM 4(b).

     

    3


    CUSIP No. 03815U409    13G   

     

     1   

     NAME OF REPORTING PERSONS

     I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

     Tony Moore

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     United States Citizen

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     1,143,104*

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     1,143,104*

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     1,143,104*

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     9.9% **

    12  

     TYPE OF REPORTING PERSON*

     

     HC, IN

     

    *

    SEE INSTRUCTIONS BEFORE FILLING OUT

    **

    SEE ITEM 4(b).

     

    4


    CUSIP No. 03815U409    13G   

     

     1   

     NAME OF REPORTING PERSONS

     I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

     Anson Advisors Inc.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Ontario, Canada

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     1,143,104*

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     1,143,104*

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     1,143,104*

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     9.9% **

    12  

     TYPE OF REPORTING PERSON*

     

     FI, CO

     

    *

    SEE INSTRUCTIONS BEFORE FILLING OUT

    **

    SEE ITEM 4(b).

     

    5


    CUSIP No. 03815U409    13G   

     

     1   

     NAME OF REPORTING PERSONS

     I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

     Amin Nathoo

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Canadian Citizen

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     1,143,104*

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     1,143,104*

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     1,143,104*

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     9.9% **

    12  

     TYPE OF REPORTING PERSON*

     

     HC, IN

     

    *

    SEE INSTRUCTIONS BEFORE FILLING OUT

    **

    SEE ITEM 4(b).

     

    6


    CUSIP No. 03815U409    13G   

     

     1   

     NAME OF REPORTING PERSONS

     I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)

     

     Moez Kassam

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

     (a) ☐  (b) ☐

     

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Canadian Citizen

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     0

       6  

     SHARED VOTING POWER

     

     1,143,104*

       7  

     SOLE DISPOSITIVE POWER

     

     0

       8  

     SHARED DISPOSITIVE POWER

     

     1,143,104*

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     1,143,104*

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*

     

     ☐

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9

     

     9.9% **

    12  

     TYPE OF REPORTING PERSON*

     

     HC, IN

     

    *

    SEE INSTRUCTIONS BEFORE FILLING OUT

    **

    SEE ITEM 4(b).

     

    7


    SCHEDULE 13G

    This Schedule 13G (the “Schedule 13G”) is being filed on behalf of Anson Funds Management LP (d/b/a Anson Funds), a Texas limited partnership, Anson Management GP LLC, a Texas limited liability company, Mr. Tony Moore, the principal of Anson Funds Management LP and Anson Management GP LLC, Anson Advisors Inc., an Ontario, Canada corporation, Mr. Amin Nathoo, a director of Anson Advisors Inc., and Mr. Moez Kassam, a director of Anson Advisors Inc., relating to Common Stock, $0.001 par value (the “Common Stock”), of Applied DNA Sciences, Inc., a Delaware corporation (the “Issuer”).

    This Schedule 13G relates to the Common Stock of the Issuer purchased by a private fund to which Anson Funds Management LP and Anson Advisors Inc. serve as co-investment advisors (the “Fund”). Anson Funds Management LP and Anson Advisors Inc. serve as co-investment advisors to the Fund and may direct the vote and disposition of the 1,143,104 shares of Common Stock held by the Fund. As the general partner of Anson Funds Management LP, Anson Management GP LLC may direct the vote and disposition of the 1,143,104 shares of Common Stock held by the Fund. As the principal of Anson Fund Management LP and Anson Management GP LLC, Mr. Moore may direct the vote and disposition of the 1,143,104 shares of Common Stock held by the Fund. As directors of Anson Advisors Inc., Mr. Nathoo and Mr. Kassam may each direct the vote and disposition of the 1,143,104 shares of Common Stock held by the Fund.

     

    Item 1(a)

    Name of Issuer.

    Applied DNA Sciences, Inc.

     

    Item 1(b)

    Address of Issuer’s Principal Executive Offices.

    50 Health Sciences Drive

    Stony Brook, NY, 11790

     

    Item 2(a)

    Name of Person Filing.

    Anson Funds Management LP, Anson Management GP LLC, Mr. Tony Moore, Anson Advisors Inc., Mr. Amin Nathoo and Mr. Moez Kassam

     

    Item 2(b)

    Address of Principal Business Office, or, if none, Residence.

    For Anson Funds Management LP, Anson Management GP LLC and Mr. Moore:

    16000 Dallas Parkway, Suite 800

    Dallas, Texas 75248

    For Anson Advisors Inc., Mr. Nathoo and Mr. Kassam:

    181 Bay Street, Suite 4200

    Toronto, ON

    M5J 2T3

     

    8


    Item 2(c)

    Citizenship or Place of Organization.

    Anson Funds Management LP is a limited partnership organized under the laws of the State of Texas. Anson Management GP LLC is a limited liability company organized under the laws of the State of Texas. Mr. Moore is a United States citizen. Anson Advisors Inc. is a corporation organized under the laws of Ontario, Canada. Mr. Nathoo and Mr. Kassam are each Canadian citizens.

     

    Item 2(d)

    Title of Class of Securities.

    Common Stock, $0.001 par value

     

    Item 2(e)

    CUSIP Number.

    03815U409

     

    Item 3

    Reporting Person.

    If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b), check whether the person filing is a:

     

    (a)    ☐    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
    (b)    ☐    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
    (c)    ☐    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
    (d)    ☐    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
    (e)    ☒    An investment advisor in accordance with §240.13d-1(b)(1)(ii)(E).
    (f)    ☐    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F).
    (g)    ☒    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G).
    (h)    ☐    A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813).
    (i)    ☐    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3).
    (j)    ☒    A non-U.S. institution that is the functional equivalent of any of the institutions listed in § 240.13d-1 (b)(1)(ii)(A) through (I), so long as the non-U.S. institution is subject to a regulatory scheme that is substantially comparable to the regulatory scheme applicable to the equivalent U.S. institution.
    (k)    ☐    Group, in accordance with §240.13d-1(b)(1)(ii)(K).

     

    9


    Item 4

    Ownership.

     

      (a)

    Anson Funds Management LP, Anson Management GP LLC, Mr. Moore, Anson Advisors Inc., Mr. Nathoo and Mr. Kassam are the beneficial owners of 1,143,104 shares of Common Stock held by the Fund.

     

      (b)

    Anson Funds Management LP, Anson Management GP LLC, Mr. Moore, Anson Advisors Inc., Mr. Nathoo and Mr. Kassam are the beneficial owners of 9.9% of the outstanding shares of Common Stock, which includes shares of Common Stock underlying outstanding warrants (each, a “Warrant,” and collectively, the “Warrants”) held by Anson Funds Management LP, Anson Management GP LLC, Mr. Moore, Anson Advisors Inc., Mr. Nathoo and Mr. Kassam. Each Warrant includes a beneficial ownership limitation. The Warrants may not be exercised to the extent the Reporting Persons would, in the case of some of the Warrants, beneficially own more than 4.99%, and in the case of others, beneficially own more than 9.99% of the outstanding Common Stock. The beneficial ownership set forth herein takes into account the foregoing limitation. This percentage is determined by dividing 1,143,104 by 11,442,489, which is the sum of: (i) 10,299,385 shares of Common Stock issued and outstanding, as reported in the Issuer’s Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the “SEC”) on August 14, 2024; and (ii) 1,143,104 the number of shares of Common Stock receivable by the Fund upon exercise of the Common Warrants.

     

      (c)

    Anson Funds Management LP and Anson Advisors Inc., as the co-investment advisors to the Fund, may direct the vote and disposition of the 1,143,104 shares of Common Stock held by the Fund. Anson Management GP LLC, as the general partner of Anson Funds Management LP, may direct the vote and disposition of the 1,143,104 shares of Common Stock held by the Fund. As the principal of Anson Funds Management LP and Anson Management GP LLC, Mr. Moore may direct the vote and disposition of the 1,143,104 shares of Common Stock held by the Fund. Mr. Nathoo and Mr. Kassam, each as a director of Anson Advisors Inc., may direct the vote and disposition of the 1,143,104 shares of Common Stock held by the Fund.

     

    Item 5

    Ownership of Five Percent or Less of a Class.

    Inapplicable.

     

    Item 6

    Ownership of More Than Five Percent on Behalf of Another Person.

    See description regarding the Fund in the introduction, which is incorporated by reference herein.

     

    Item 7

    Identification and Classification of the Subsidiary which Acquired the Security Being Reported On by the Parent Holding Company.

    See description of control persons of Anson Funds Management LP and Anson Advisors Inc. in the introduction, which is incorporated by reference herein.

     

    Item 8

    Identification and Classification of Members of the Group.

    Inapplicable.

     

    Item 9

    Notice of Dissolution of Group.

    Inapplicable.

     

    Item 10

    Certification.

    By signing below each of the Reporting Persons certifies that, to the best of such person’s knowledge and belief, the securities referred to above were acquired and held in the ordinary course of business and were not acquired and were not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    10


    For Anson Advisors Inc.:

    By signing below I certify that, to the best of my knowledge and belief, the foreign regulatory scheme applicable to portfolio managers and exempt market dealers is substantially comparable to the regulatory scheme applicable to the functionally equivalent U.S. institution. I also undertake to furnish to the Commission staff, upon request, information that would otherwise be disclosed in a Schedule 13D.

     

    Exhibits

    Exhibit 99.1

    Joint Filing Agreement dated November 14, 2024, by and among Anson Funds Management LP, Anson Management GP LLC, Mr. Moore, Anson Advisors Inc., Mr. Nathoo and Mr. Kassam.

     

    11


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: November 14, 2024

     

    ANSON FUNDS MANAGEMENT LP
    By: Anson Management GP LLC, its general partner
    By:   /s/ Tony Moore
      Tony Moore
      Manager
    ANSON MANAGEMENT GP LLC
    By:   /s/ Tony Moore
      Tony Moore
      Manager
    /s/ Tony Moore
    Tony Moore
    ANSON ADVISORS INC.
    By:   /s/ Amin Nathoo
      Amin Nathoo
      Director
    By:   /s/ Moez Kassam
      Moez Kassam
      Director
    /s/ Amin Nathoo
    Amin Nathoo
    /s/ Moez Kassam
    Moez Kassam

     

     

    12

    Get the next $APDN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $APDN

    DatePrice TargetRatingAnalyst
    2/11/2022$8.00 → $6.00Buy
    HC Wainwright & Co.
    8/13/2021$13.00 → $11.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $APDN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Applied DNA Sciences Inc.

      SC 13G - APPLIED DNA SCIENCES INC (0000744452) (Subject)

      11/14/24 5:46:25 PM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by Applied DNA Sciences Inc.

      SC 13G/A - APPLIED DNA SCIENCES INC (0000744452) (Subject)

      11/13/24 4:15:25 PM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by Applied DNA Sciences Inc.

      SC 13G/A - APPLIED DNA SCIENCES INC (0000744452) (Subject)

      11/7/24 10:11:34 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary

    $APDN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Jantzen Beth

      4 - APPLIED DNA SCIENCES INC (0000744452) (Issuer)

      3/27/23 9:30:56 PM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • SEC Form 4 filed by Shorrock Clay

      4 - APPLIED DNA SCIENCES INC (0000744452) (Issuer)

      3/27/23 9:30:40 PM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • SEC Form 4 filed by Murrah Judith

      4 - APPLIED DNA SCIENCES INC (0000744452) (Issuer)

      3/27/23 9:30:30 PM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary

    $APDN
    Financials

    Live finance-specific insights

    See more
    • Applied DNA to Report Fourth Quarter and Fiscal Year 2024 Financial Results After Market Close on December 17, 2024; Sets Webcast and Conference Call for January 9, 2025, to Coincide with Update on GMP Manufacturing Facility Build-out

      STONY BROOK, NY / ACCESSWIRE / December 16, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its fourth quarter and fiscal year 2024 financial results after the market close on Tuesday, December 17, 2024.The Company will host a conference call for the investment community to coincide with an update on its GMP manufacturing facility build-out on Thursday, January 9, 2025, at 4:30 p.m. ET.Webcast and Conference Call Date & Time: Thursday, January 9 @ 4:30 p.m. ETDial In:Domestic callers (toll free): 844-887-9402International callers: 412-317-6798Canadian callers

      12/16/24 10:00:00 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • Applied DNA to Report Third Quarter Fiscal 2024 Financial Results on Thursday, August 8, 2024

      STONY BROOK, NY / ACCESSWIRE / August 7, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its third quarter fiscal 2024 financial results after market close on Thursday, August 8, 2024. In conjunction with this announcement, Applied DNA management will host a conference call for analysts and members of the investment community starting at 4:30 p.m. ET the same day. On this call, management will discuss the Company's financial results and recent accomplishments.Date & Time: Thursday, August 8 @ 4:30 p.m. ETDial In:Domestic callers (toll free): 844-887-9402Inter

      8/7/24 8:00:00 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • Applied DNA Announces Second Quarter Fiscal Year 2024 Financial Results

      STONY BROOK, NY / ACCESSWIRE / May 10, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced consolidated financial results for its second fiscal quarter ended March 31, 2024. The Company's Form 10-Q can be viewed at https://investors.adnas.com/sec-filings/. The Company will not host a financial webcast or call for this most recent quarterly reporting period. The Company will host an investor update call on June 12, 2024.Summary Second Quarter Fiscal 2024 Financial Results:Total revenues were approximately $930 thousand for the three-month period March 31, 2024, compared to $4.4 million for the second quarter

      5/10/24 4:05:00 PM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary

    $APDN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Applied DNA Sciences with a new price target

      HC Wainwright & Co. reiterated coverage of Applied DNA Sciences with a rating of Buy and set a new price target of $6.00 from $8.00 previously

      2/11/22 6:29:21 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • HC Wainwright & Co. reiterated coverage on Applied DNA Sciences with a new price target

      HC Wainwright & Co. reiterated coverage of Applied DNA Sciences with a rating of Buy and set a new price target of $11.00 from $13.00 previously

      8/13/21 6:30:16 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • HC Wainwright & Co. reiterated coverage on Applied DNA Sciences with a new price target

      HC Wainwright & Co. reiterated coverage of Applied DNA Sciences with a rating of Buy and set a new price target of $13.00 from $14.00 previously

      4/22/21 6:37:35 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary

    $APDN
    SEC Filings

    See more
    • Applied DNA Sciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - APPLIED DNA SCIENCES INC (0000744452) (Filer)

      6/6/25 2:28:36 PM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • Applied DNA Sciences Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - APPLIED DNA SCIENCES INC (0000744452) (Filer)

      5/29/25 8:15:36 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • Applied DNA Sciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - APPLIED DNA SCIENCES INC (0000744452) (Filer)

      5/22/25 4:10:46 PM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary

    $APDN
    Leadership Updates

    Live Leadership Updates

    See more
    • Applied DNA Advances Commercialization of Linea(TM) IVT Platform, Appoints Beverly Wolgast as Executive Director of Quality and cGMP Programs

      Experienced Biopharma/Pharmaceutical Executive to Lead Implementation of cGMP-quality LineaDNA™ Capability for IVT mRNA ProductionPreviously Led Manufacturing Operations Scale-up for the BioNTech/Pfizer mRNA COVID-19 Vaccine at CDMO Division of Maravai LifeSciencesSTONY BROOK, NY / ACCESSWIRE / September 6, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the appointment of Beverly Wolgast, Ph.D., as executive director of Quality and cGMP Programs. Dr. Wolgast will oversee and manage Applied DNA's quality assurance and control and regulatory compliance spanning the Company's three business segments, incl

      9/6/23 9:00:00 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • Applied DNA Appoints Clay Shorrock as Chief Legal Officer and Executive Director of Business Development

      STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that Clay Shorrock, J.D., has rejoined the Company effective immediately to serve on the executive leadership team as Chief Legal Officer and Executive Director, Business Development. In this newly created role, Mr. Shorrock will lead Applied DNA’s legal, regulatory, IP, and business development functions. Dr. James A. Hayward, president and CEO, Applied DNA, said, “As we continue to advance the adoption of our PCR-based, LinearDNATM manufacturing platform across highly regulated markets and further devel

      4/1/21 8:00:00 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary

    $APDN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates

      - Signals Start of New Commercialization Phase for LineaRx Subsidiary -- Company Negotiating GMP Supply Agreement -- Company Reaffirms Strategic Restructuring Timeline - STONY BROOK, NY / ACCESSWIRE / January 10, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the completion of the buildout of its new Good Manufacturing Practices (GMP) manufacturing facility (the "facility") within its Stony Brook, New York, headquarters and readiness to accept orders for the manufacture of LineaDNA™ IVT templates that clients can utilize for the production of mRNA clinical trial materials. The facility is undergoing fi

      1/10/25 9:00:00 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • Applied DNA Reschedules Investor Update Call in Observance of the National Day of Mourning in Recognition of the Passing of Former President Jimmy Carter

      STONY BROOK, NY / ACCESSWIRE / January 8, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it has rescheduled its Investor Update call to Thursday, February 13, 2025, to coincide with the release of its first quarter fiscal 2025 financial results.The Company originally scheduled an Investor Update call for January 9, 2025, to update shareholders on its strategic restructuring announced in December 2024 and GMP initiative. The change reflects the observance of the National Day of Mourning in recognition of the passing of former President Jimmy Carter.About Applied DNA Sciences

      1/8/25 4:30:00 PM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA

      - Regulatory Approval Showcases Clinical Advancement of Linea DNA™ as a Rapid and Effective Means of Producing CAR-T cell Therapies -STONY BROOK, NY / ACCESSWIRE / December 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, announced that the State Institute for Drug Control of the Czech Republic (SÚKL) approved an application for a Phase I clinical trial of an investigational CD123-specific autologous CAR T-cell therapy by the Institute of Hematology and Blood Transfusion (ÚHKT/Eng: IHBT) in Prague for the treatment of relapsed and/or refractory acute myeloid leukemia (AML). UHKT-CAR123-01 utilizes Applied DNA's synt

      12/18/24 9:00:00 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary